PremiumWeekend UpdatesPerion, Sea, KKR, Chimera, AbbVie: Trending by Analysts Chimera upgraded to Buy from Neutral at UBS Chimera Investment: Buy Rating Upgraded on Optimized Liabilities and Promising ROE Growth PremiumPre-EarningsIs CIM a Buy, Before Earnings? Chimera Investment Board Member Resigns Abruptly Chimera Investment Announces Officer Departure PremiumCompany AnnouncementsChimera Investment Corporation Announces Mixed 2024 Earnings Chimera reports Q4 EPS 37c, consensus 38c Chimera Investment Declares Q1 2025 Preferred Dividends